Sumatriptan
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | ZEMBRACE SYMTOUCH | — | 2019-06-10 | fda.gov ↗ |
| Label expansion | US (FDA) | SUMAVEL DOSEPRO | — | 2013-11-26 | fda.gov ↗ |
| Refused (EMA) | EU (EMA) | Sumatriptan Galpharm | — | 2012-02-09 | europa.eu ↗ |
| Label expansions (2) | US (FDA) | IMITREX STATDOSE | — | 1996-05-22 – 2006-02-01 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | IMITREX | — | 1998-02-13 – 2004-10-13 | fda.gov ↗ |
| Approved | US (FDA) | IMITREX STATDOSE | — | 1992-12-28 | fda.gov ↗ |
Trials 60 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04690270 | Jan → Jun 2021 | obesity disorder | Cambridge University Hospitals NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 120 trials | ||||||
| Phase 1 | NCT05064488 | Oct → Dec 2021 | — | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1 | NCT04355845 | Jun → Aug 2020 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04197349 | Sep 2019 → Aug 2020 | migraine disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT03310411 | Oct → Dec 2017 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03076970 | Mar → Apr 2017 | migraine disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02932488 | Sep 2016 → Jun 2019 | — | Gitte Moos Knudsen | Terminated | No outcome recorded |
| Phase 1 | NCT02954276 | Mar → Aug 2016 | migraine disorder | Targia Pharmaceuticals Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02741310 | Feb → Aug 2016 | — | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT02684409 | Aug 2013 → Nov 2014 | migraine disorder | NuPathe Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02054299 | Apr 2013 → Feb 2016 | — | University Medical Center Goettingen | Completed | No outcome recorded |
| Phase 1 | NCT01579383 | Apr → Dec 2012 | migraine disorder | Alder Biopharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01507610 | Jan → Feb 2012 | migraine disorder | Optinose US Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01381796 | Dec 2009 → Sep 2010 | — | NuPathe Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00723983 | Nov 2008 → Sep 2009 | migraine disorder | NuPathe Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00720018 | Jun → Jul 2008 | migraine disorder | NuPathe Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00620425 | Dec 2007 | — | Zogenix, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00701389 | Nov 2007 → Apr 2008 | migraine disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00648466 | Nov → Dec 2004 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00650247 | Nov 2004 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00847405 | Mar 2003 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT03877718 | Feb → Aug 2019 | migraine disorder | Charleston Laboratories, Inc | Completed | No outcome recorded |
| Phase 2 | NCT02856802 | Jul 2016 → Feb 2017 | migraine disorder | Upsher-Smith Laboratories | Completed | No outcome recorded |
| Phase 2 | NCT02571049 | Sep 2015 → Apr 2016 | migraine disorder | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 2 | NCT01854385 | Jun 2013 → Feb 2018 | — | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT01791400 | Jul 2009 → Nov 2010 | migraine disorder | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01016678 | Mar 2010 → Jun 2014 | migraine disorder | Premiere Research Institute | Completed | No outcome recorded |
| Phase 323 trials | ||||||
| Phase 3 | NCT04948164 | Aug 2018 → Dec 2021 | migraine disorder | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03338920 | Nov 2017 → Apr 2022 | migraine disorder | Currax Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT02569853 | Sep 2015 → May 2017 | migraine disorder | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 3 | NCT02279082 | Sep 2014 → Sep 2015 | migraine disorder | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 3 | NCT00806546 | Feb 2009 → May 2011 | migraine disorder | NuPathe Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00792103 | Jan 2009 → Sep 2010 | migraine disorder | NuPathe Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00724815 | Jan → Jul 2009 | migraine disorder | NuPathe Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00843024 | Dec 2008 → May 2010 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00573170 | Feb 2008 → Aug 2009 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00488514 | Jul 2007 → Aug 2009 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00510419 | Jul → Dec 2007 | migraine disorder | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00382993 | Dec 2006 → Nov 2007 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00383162 | Nov 2006 → Oct 2007 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00385008 | Sep → Nov 2006 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00387881 | Sep 2006 → Feb 2008 | migraine without aura | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00356603 | Jun → Aug 2006 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00329459 | May → Nov 2006 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00329355 | May → Nov 2006 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00433732 | Aug 2004 → Apr 2005 | migraine disorder | POZEN | Completed | No outcome recorded |
| Phase 3 | NCT00434083 | Jul 2004 → Jan 2005 | migraine disorder | POZEN | Completed | No outcome recorded |
| Phase 3 | NCT01986270 | Dec 1996 → Jan 1998 | migraine disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01986088 | Nov 1996 → Jan 1998 | migraine disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00897104 | Aug 1995 → May 1996 | migraine disorder | Organon and Co | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT01807234 | Feb 2013 → Dec 2014 | migraine disorder | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT01071317 | Feb 2010 → Jan 2012 | migraine disorder | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01016834 | Nov 2009 → Apr 2010 | migraine disorder | Zogenix, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00893737 | Jun 2009 → Jan 2010 | migraine disorder | Cady, Roger, M.D. | Completed | No outcome recorded |
| Phase 4 | NCT00792636 | Nov 2008 → Nov 2009 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00399243 | Nov 2006 → Aug 2010 | cluster headache syndrome | Diamond Headache Clinic | Unknown | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT07515456 | Dec 2024 → Nov 2026 expected | intracranial hypotension | Tanta University | Recruiting | No outcome recorded |
| — | NCT05654298 | Mar 2022 → Mar 2023 | migraine disorder | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| — | NCT01632657 | Jun 2012 → Oct 2019 | — | University Health Network, Toronto | Completed | No outcome recorded |
| — | NCT00399633 | Jan → Apr 2007 | migraine disorder | Danish Headache Center | Completed | No outcome recorded |
Also used as a comparator or background therapy in 49 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT03229798 Comparator | Jan → Mar 2018 | migraine disorder | Sorrento Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00989625 Comparator | Nov 2008 → Sep 2009 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00875784 Comparator | May → Jun 2008 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00546650 Comparator | Nov → Dec 2007 | — | NuPathe Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00846885 Comparator | Aug → Sep 2004 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT02176655 Comparator | Jul 2014 → Jan 2016 | alcohol-induced mental disorder | Cady, Roger, M.D. | Completed | No outcome recorded |
| Phase 2 | NCT01430442 Comparator | Oct 2011 → May 2012 | migraine disorder | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00920686 Comparator | Jun 2009 → Mar 2010 | migraine with aura | NeurAxon Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00892203 Comparator | Apr 2009 → Aug 2010 | migraine disorder | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00804973 Comparator | Nov 2008 → May 2009 | migraine disorder | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03185143 Comparator | Jun 2017 → May 2018 | migraine disorder | Allodynic Therapeutics, Inc | Completed | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT01814189 Comparator | Jan → Apr 2013 | migraine with aura, migraine without aura | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01667679 Comparator | Aug 2012 → Mar 2014 | migraine disorder | Avanir Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01462812 Comparator | Jan 2011 → Jun 2012 | migraine disorder | Optinose US Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00963937 Comparator | Sep 2009 → Dec 2010 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00894556 Background | Jun 2009 → Jan 2010 | migraine disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00240617 Comparator | Oct 2005 → Jun 2006 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00240630 Comparator | Oct 2005 → Jun 2006 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00442221 Background | May → Aug 2004 | migraine disorder | POZEN | Completed | No outcome recorded |
| Phase 3 | NCT00898677 Comparator | Sep 1995 → May 1996 | migraine disorder | Organon and Co | Completed | No outcome recorded |
| Phase 415 trials | ||||||
| Phase 4 | NCT07022496 Background | Apr 2023 → Jul 2025 overdue | migraine disorder | Ain Shams University | Recruiting | No outcome recorded |
| Phase 4 | NCT05108688 Comparator | Nov 2021 → Dec 2023 | headache disorder | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT04257851 Comparator | Feb 2020 → May 2021 | intracranial hypotension | Damanhour Teaching Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02670161 Comparator | May 2016 → Dec 2026 expected | Parkinson disease, brain neoplasm, cognitive impairment with or without cerebellar ataxia, epilepsy +6 | Endeavor Health | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT01329562 Comparator | May 2011 → Jun 2012 | migraine disorder | Cady, Roger, M.D. | Completed | No outcome recorded |
| Phase 4 | NCT01300546 Comparator | Dec 2010 → Apr 2012 | migraine disorder | Cady, Roger, M.D. | Completed | No outcome recorded |
| Phase 4 | NCT01248468 Comparator | Nov 2010 → Mar 2011 | migraine disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT01090050 Comparator | Sep 2010 → Jun 2012 | migraine disorder | Cady, Roger, M.D. | Completed | No outcome recorded |
| Phase 4 | NCT01053507 Comparator | May 2010 → Nov 2012 | traumatic encephalopathy | Cady, Roger, M.D. | Terminated | No outcome recorded |
| Phase 4 | NCT01450995 Comparator | Dec 2009 → May 2011 | migraine disorder | Stephen H. Landy, M.D. | Completed | No outcome recorded |
| Phase 4 | NCT01086358 Comparator | Sep 2009 → Aug 2016 | — | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 4 | NCT01138150 Comparator | Sep 2009 → Jun 2013 | migraine disorder | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT01476930 Comparator | Jun 2008 → Sep 2009 | migraine disorder | Birjand University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00449787 Comparator | Mar 2007 → Jul 2009 | migraine disorder | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00910689 Comparator | Jul 2001 → Nov 2005 | migraine disorder | Ohio University | Completed | No outcome recorded |
| Phase not applicable14 trials | ||||||
| — | NCT06617832 Comparator | Nov 2024 → Sep 2028 expected | migraine with aura, migraine without aura | University of Aarhus | Recruiting | No outcome recorded |
| — | NCT06514040 Comparator | Nov 2023 → Aug 2024 | intracranial hypotension | Fayoum University Hospital | Completed | No outcome recorded |
| — | NCT05211050 Comparator | Mar 2022 → Nov 2023 | migraine without aura | Danish Headache Center | Completed | No outcome recorded |
| — | NCT03878784 Comparator | Nov 2018 → Dec 2019 | rosacea | Danish Headache Center | Completed | No outcome recorded |
| — | NCT03881644 Comparator | Jul 2018 → Dec 2019 | migraine without aura | Danish Headache Center | Completed | No outcome recorded |
| — | NCT03542357 Comparator | Feb → Sep 2018 | migraine disorder | Danish Headache Center | Completed | No outcome recorded |
| — | NCT03422796 Comparator | Nov 2017 → Sep 2018 | migraine disorder | Danish Headache Center | Completed | No outcome recorded |
| — | NCT03156920 Comparator | May → Oct 2017 | migraine disorder | Danish Headache Center | Completed | No outcome recorded |
| — | NCT02643719 Comparator | Dec 2015 → Oct 2017 | migraine disorder | NYU Langone Health | Withdrawn | No outcome recorded |
| — | NCT02486276 Comparator | Jun 2015 → Jun 2016 | migraine disorder | Danish Headache Center | Completed | No outcome recorded |
| — | NCT02485340 Comparator | Apr → Aug 2015 | migraine disorder | Danish Headache Center | Completed | No outcome recorded |
| — | NCT00893594 Comparator | Oct 2010 → Dec 2015 | migraine with aura | Dent Neurologic Institute | Unknown | No outcome recorded |
| — | NCT00837044 Comparator | Feb → Jul 2009 | cognitive disorder, migraine disorder | Neurological Research Center | Unknown | No outcome recorded |
| — | NCT00573599 Comparator | Feb → May 2007 | migraine disorder | United States Naval Medical Center, Portsmouth | Withdrawn | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2016-06-27 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva and Antares Pharma Announce Launch of Generic Imitrex® in the United States tevapharm.com ↗ |
| 2015-09-01 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces U.S. Availability of ZECUITY® (sumatriptan iontophoretic transdermal system), First and Only Transdermal Patch System for the Acute Treatment of Migraine tevapharm.com ↗ |
| 2009-02-11 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval and Launch of Generic Imitrex® Tablets tevapharm.com ↗ |
| 2006-11-29 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval Of Sumatriptan Succinate Tablets tevapharm.com ↗ |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 112 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sumatriptan | “This randomized, open-label, 3-period crossover study compared the exposure to sumatriptan (Cmax and AUC to 14 hours after the administration of the second dose [AUC(0-14)])...” PMID 20637969 ↗ Jun 2010100“The choice of triptans (rizatriptan®, sumatriptan®), the route(s) of triptan administration (oral, nasal spray, subcutaneous injection), and the addition of a NSAID, or...” NCT00910689 ↗ “Adult subjects who meet the enrollment criteria will be treated with NP101 (sumatriptan succinate iontophoretic transdermal patch) for acute migraine attacks over a 12 month period.” NCT00806546 ↗ “One tablet of sumatriptan 85 mg and naproxen sodium 500 mg will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.” NCT01138150 ↗ “BACKGROUND: DFN-11, a 3 mg sumatriptan subcutaneous (SC) autoinjector for acute treatment of migraine, has not been assessed previously in multiple attacks.” PMID 30112725 ↗ Aug 2018 “One sumatriptan succinate 12.5 mg combined with acetylsalicylic acid 325 mg (VVD-101) capsule taken after the onset of a delayed alcohol induced headache.” NCT02176655 ↗ “Treximet(tm) is a triptan tablet containing a combination of sumatriptan 85mg (Imitrex) and naproxen sodium 500 mg.” NCT01450995 ↗ “ComboProduct Containing Sumatriptan and Naproxen Sodium for Acute Treatment of Migraine in Adolescents” NCT01016678 ↗ “NP101, a transdermal sumatriptan formulation in development for the acute treatment of migraine” PMID 22352764 ↗ Feb 2012 “with sumatriptan-naproxen (Treximet®) or placebo in a double-blind, placebo-controlled fashion” PMID 23406052 ↗ Feb 2013 “Standard dose of Sumatriptan 100 mg, which is used as an acute treatment for episodic migraine” NCT06617832 ↗ “BACKGROUND: DFN-02 is a novel intranasal spray formulation composed of sumatriptan 10 mg” PMID 28251391 ↗ Mar 2017 “Tablet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg.” NCT01329562 ↗ “nortriptyline ,propranolol ,ergotamine , sumatriptan tablets” NCT01476930 ↗ “Treximet is 85 mg sumatriptan plus 500 mg naproxen sodium” NCT01086358 ↗ “migraine (sumatriptan, rizatriptan, zolmitriptan)” NCT02670161 ↗ “TREXIMET® (Sumatriptan + Naproxen Sodium)” NCT00573170 ↗ “oral sumatriptan succinate” NCT01381796 ↗ “Sumatriptan” NCT00724815 ↗ “Sumatriptan” NCT02684409 ↗ “Sumatriptan” NCT07022496 ↗ |
| Known as | Alsuma() | “a novel sumatriptan auto-injector (Alsuma(®)), and to evaluate the safety, tolerability, and effectiveness of this sumatriptan auto-injector during an acute migraine attack.” PMID 23148799 ↗ Nov 2012 |
| Known as | DFN-02 | “A safety and efficacy study of DFN-02 (Sumatriptan Nasal Spray 10 mg), being conducted at multiple centers in the United States.” NCT02856802 ↗ |
| Known as | DFN-11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02571049 ↗ |
| Known as | Imigran | “Sumatriptan (Imigran) is a selective serotonin receptor agonist. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and...” NCT06514040 ↗ |
| Known as | Imitrex | “the trial is a randomized, open label, crossover, single-administration bioavailability study to compare the pharmacokinetic parameters of Omexa sumatriptan transmucosal...” NCT02954276 ↗8“This is a randomized, double-blind, three-period, cross-over study to investigate the effect of sumatriptan (Imitrex) 100 mg on the pharmacodynamics and pharmacokinetics of...” NCT03076970 ↗ “IMITREX® (sumatriptan succinate) Injection 4mg administered using the IMITREX STATdose System®” NCT00875784 ↗ “20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray” NCT01507610 ↗ “100 mg oral tablet commercial Imitrex sumatriptan succinate tablet” NCT03229798 ↗ “Sumatriptan succinate (Imitrex®) tablet: 100 mg orally.” NCT00546650 ↗ |
| Known as | NP101 | “A Phase I, Open Label, Single-Dose, Four-Way Crossover Study Comparing the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) With an Oral Formulation of...” NCT00723983 ↗6“Adult subjects who meet the enrollment criteria will be treated with NP101 (sumatriptan succinate iontophoretic transdermal patch) for acute migraine attacks over a 12 month period.” NCT00806546 ↗ “A Phase I, Single Center, Open Label, Single-Dose, Five-Period Study to Compare the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) in Healthy Volunteers” NCT00720018 ↗ “OBJECTIVE: To assess the long-term tolerability and efficacy of NP101, a novel transdermal sumatriptan patch being developed for the acute treatment of migraine.” PMID 22352764 ↗ Feb 2012 “Two NP101 (Sumatriptan Iontophoretic Transdermal Patch) With an Oral Formulation of Imitrex” NCT01381796 ↗ “NP101 (Sumatriptan Iontophoretic Transdermal Patch)” NCT00546650 ↗ “NP101 - sumatriptan iontophoretic transdermal patch” NCT00724815 ↗ |
| Known as | Omexa | “the trial is a randomized, open label, crossover, single-administration bioavailability study to compare the pharmacokinetic parameters of Omexa sumatriptan transmucosal...” NCT02954276 ↗ |
| Known as | OPTINOSE SUMATRIPTAN | “20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray” NCT01507610 ↗ |
| Known as | sumatriptan succinate | “Adult subjects who meet the enrollment criteria will be treated with NP101 (sumatriptan succinate iontophoretic transdermal patch) for acute migraine attacks over a 12 month period.” NCT00806546 ↗12“Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer” NCT00383162 ↗ “fixed dose combination tablet of sumatriptan succinate [equivalent to sumatriptan 85mg] and naproxen sodium 500mg” NCT00573170 ↗ “IMITREX® (sumatriptan succinate) Injection 4mg administered using the IMITREX STATdose System®” NCT00875784 ↗ “One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 18.75 mg)” NCT03877718 ↗ “Combination Product (sumatriptan succinate / naproxen sodium)” NCT00385008 ↗ “Sumatriptan succinate (Imitrex®) tablet: 100 mg orally.” NCT00546650 ↗ “Treatment C - oral sumatriptan succinate” NCT01381796 ↗ “Sumatriptan Succinate Tablets 100 mg” NCT00648466 ↗ “sumatriptan succinate 100 mg” NCT00920686 ↗ |
| Known as | Sumigran 25 | “Patients included in this group will receive oral 25 mg sumatriptan succinate tablet (Sumigran 25, 25 mg tablet, Sigma pharmaceutical industries, Egypt) every 12 hours.” NCT07515456 ↗ |
| Action | Activate | “The receptor can be stimulated with the agonist sumatriptan” NCT02932488 ↗ |
| Route | Oral | “sumatriptan succinate/naproxen sodium) tablets vs placebo” NCT00329355 ↗ |